Cladribine for Waldenström's macroglobulinaemia. 1999

A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008258 Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity. Lymphoma, Lymphoplasmacytoid,Macroglobulinemia,Familial Waldenstrom's Macroglobulinaemia,Lymphoma, Lymphocytic, Plasmacytoid,Primary Macroglobulinemia,Waldenstrom's Macroglobulinaemia,Waldenstrom's Macroglobulinemia,Familial Waldenstrom Macroglobulinaemia,Familial Waldenstroms Macroglobulinaemia,Lymphomas, Lymphoplasmacytoid,Lymphoplasmacytoid Lymphoma,Lymphoplasmacytoid Lymphomas,Macroglobulinaemia, Familial Waldenstrom's,Macroglobulinaemia, Waldenstrom's,Macroglobulinemia, Primary,Macroglobulinemia, Waldenstrom,Macroglobulinemia, Waldenstrom's,Waldenstrom Macroglobulinaemia,Waldenstrom's Macroglobulinaemia, Familial,Waldenstroms Macroglobulinaemia,Waldenstroms Macroglobulinemia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017338 Cladribine An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. 2-Chloro-2'-deoxyadenosine,2-Chlorodeoxyadenosine,2'-Deoxy-2-chloroadenosine,Leustatin
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
September 2002, Blood reviews,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
August 1985, Lancet (London, England),
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
September 2003, Clinical and experimental dermatology,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
July 1999, Leukemia & lymphoma,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
July 1999, British journal of haematology,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
January 2005, Clinical and experimental dermatology,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
November 1979, Journal of the Royal Society of Medicine,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
June 1957, Proceedings of the Royal Society of Medicine,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
March 1974, Journal of the neurological sciences,
A Delannoy, and E Van Den Neste, and J L Michaux, and A Bosly, and A Ferrant
February 2022, Australian prescriber,
Copied contents to your clipboard!